Unknown

Dataset Information

0

The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy.

ABSTRACT: CBP-93872 suppresses maintenance of DNA double-stranded break-induced G2 checkpoint, by inhibiting the pathway between ataxia-telangiectasia mutated (ATM) and ATM- and Rad3-related (ATR) activation. To examine the potential use of CBP-93872 for clinical applications, we analyzed the synergistic effects of platinum-containing drugs, oxaliplatin and cisplatin, pyrimidine antimetabolites, gemcitabine and 5-fluorouracil (5-FU), in combination with CBP-93872, on cell lethality in colorectal and pancreatic cancer cell lines. Treatment with CBP-93872 significantly increased cancer cell sensitivities to various chemotherapeutic agents tested through suppression of checkpoint activation. Our results thus reveal that combination treatment of CBP-93872 with known chemotherapeutic agents inhibits phosphorylation of ATR and Chk1, and induces cell death.

SUBMITTER: Iwata T 

PROVIDER: S-EPMC5448762 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy.

Iwata Tsutomu T   Uchino Tairin T   Koyama Ayako A   Johmura Yoshikazu Y   Koyama Kenichi K   Saito Takuya T   Ishiguro Seiji S   Arikawa Takashi T   Komatsu Shunichiro S   Miyachi Masahiko M   Sano Tsuyoshi T   Nakanishi Makoto M   Shimada Midori M  

PloS one 20170530 5

CBP-93872 suppresses maintenance of DNA double-stranded break-induced G2 checkpoint, by inhibiting the pathway between ataxia-telangiectasia mutated (ATM) and ATM- and Rad3-related (ATR) activation. To examine the potential use of CBP-93872 for clinical applications, we analyzed the synergistic effects of platinum-containing drugs, oxaliplatin and cisplatin, pyrimidine antimetabolites, gemcitabine and 5-fluorouracil (5-FU), in combination with CBP-93872, on cell lethality in colorectal and pancr  ...[more]

Similar Datasets

Unknown The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
| S-EPMC3461814 | biostudies-literature
Unknown The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells.
| S-EPMC9688551 | biostudies-literature
Unknown The REGγ inhibitor NIP30 increases sensitivity to chemotherapy in p53-deficient tumor cells.
| S-EPMC7413384 | biostudies-literature
Transcriptomics The NAMPT inhibitor FK866 increases metformin sensitivity in pancreatic cancer cells
2023-06-01 | GSE210562 | GEO
Unknown RFPL4A increases the G1 population and decreases sensitivity to chemotherapy in human colorectal cancer cells.
| S-EPMC4358269 | biostudies-literature
Unknown Nrf2 inhibition increases sensitivity to chemotherapy of colorectal cancer by promoting ferroptosis and pyroptosis.
| S-EPMC10474100 | biostudies-literature
Unknown FEN1 inhibitor increases sensitivity of radiotherapy in cervical cancer cells.
| S-EPMC6912068 | biostudies-literature
Genomics The NAMPT inhibitor FK866 increases metformin sensitivity in pancreatic cancer cells
| PRJNA866164 | ENA
Unknown ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5‑fluorouracil by inhibiting repair of DNA damage.
| S-EPMC8892626 | biostudies-literature
Unknown Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade.
| S-EPMC9338739 | biostudies-literature